Tivicay FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved August 12, 2013)
Brand name: Tivicay
Generic name: dolutegravir
Dosage form: Tablets
Company: ViiV Healthcare
Treatment for: HIV Infection
Tivicay (dolutegravir) is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) indicated for use in combination with other antiretroviral (ARV) agents for the treatment of HIV-1.
Development timeline for Tivicay
| Date | Article |
|---|---|
| Jun 12, 2020 | Approval FDA Approves Tivicay PD (dolutegravir) Once-Daily Dispersible Tablet Formulation for Children with HIV |
| Aug 12, 2013 | Approval FDA Approves Tivicay (dolutegravir) to Treat HIV Infection |
| Dec 18, 2012 | ViiV Healthcare Announces Regulatory Submissions for Dolutegravir in the EU, US and Canada |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
